Importance of signaling via the IFN-α/β receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor

Cancer Immunology, Immunotherapy

Volumn 55, Issue 4, 2006, Pages 459-468

  Mokyr, Margalit B ^a   Place, Aaron T ^a   Artwohl, James E ^a   Valli, V E Ted ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Cancer therapy; IFN ; Immunomodulation by anticancer drugs

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA INTERFERON RECEPTOR; CYCLOPHOSPHAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; HISTOPATHOLOGY; HOST CELL; IMMUNOMODULATION; LOW DRUG DOSE; LYMPHOCYTE MIGRATION; MOUSE; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TISSUE SECTION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL MOVEMENT; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNITY, CELLULAR; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; PLASMACYTOMA; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 30444439232     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0029-2     Document Type: Article

References (43)

1. Awwad M, North RJ (1989) Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res 49:1649
2. Bass KK, Mastrangelo MJ (1998) Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother 47:1
3. Belardelli F, Ferrantini M, Santini SM, Baccarini S, Proietti E, Colombo MP, Sprent J, Tough DF (1998) The induction of in vivo proliferation of long-lived CD44hi CD8+ T cells after the injection of tumor cells expressing IFN-alpha1 into syngeneic mice. Cancer Res 58:5795
4. Berd D, Mastrangelo MJ (1988) Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Invest 6:337
5. Chawla-Sarkar M, Leaman DW, Borden EC (2001) Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res 7:1821
6. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, Lin W, Boyd JG, Moser B, Wood DE, Sahagan BG, Neote K (1998) Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 187:2009
7. Deonarain R, Verma A, Porter AC, Gewert DR, Platanias LC, Fish EN (2003) Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha. Proc Natl Acad Sci USA 100:13453
8. Donepudi M, Raychaudhuri P, Bluestone JA, Mokyr MB (2001) Mechanism of melphalan-induced B7-1 gene expression in P815 tumor cells. J Immunol 166:6491
9. Gehring S, Gregory SH, Kuzushita N, Wands JR (2005) Type 1 interferon augments DNA-based vaccination against hepatitis C virus core protein. J Med Virol 75:249
10. Giandomenico V, Vaccari G, Fiorucci G, Percario Z, Vannuchi S, Matarrese P, Malorni W, Romeo G, Affabris GR (1998) Apoptosis and growth inhibition of squamous carcinoma cells treated with interferon-alpha, IFN-beta and retinoic acid are associated with induction of the cyclin-dependent kinase inhibitor p21. Eur Cytokine Netw 9:619
11. Gorelik L, Mokyr MB (1995) Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon gamma in the therapeutic outcome. Cancer Immunol Immunother 41:363
12. Gorelik L, Prokhorova A, Mokyr MB (1994) Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother 39:117
13. Hengst JC, Mokyr MB, Dray S (1980) Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice. Cancer Res 40:2135
14. Hengst JC, Mokyr MB, Dray S (1981) Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. Cancer Res 41:2163
15. Hiroishi K, Tuting T, Lotze MT (2000) IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. J Immunol 164:567
16. Inagawa H, Nishizawa T, Honda T, Nakamoto T, Takagi K, Soma G (1998) Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions. Anticancer Res 18:3957
17. Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW (1992) Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta. J Natl Cancer Inst 84:1185
18. Jovasevic VM, Mokyr MB (2001) Melphalan-induced expression of IFN-beta in MOPC-315 tumor-bearing mice and its importance for the up-regulation of TNF-alpha expression. J Immunol 167:4895
19. Lattime EC, Mastrangelo MJ, Bagasra O, Li W, Berd D (1995) Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol Immunother 41:151
20. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF (2001) Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14:461
21. Leib DA, Machalek MA, Williams BR, Silverman RH, Virgin HW (2000) Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. Proc Natl Acad Sci USA 97:6097
22. Marie I, Durbin JE, Levy DE (1998) Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J 17:6660
23. Matar P, Rozados VR, Gervasoni SI, Scharovsky GO (2002) Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother 50:588
24. Matar P, Rozados VR, Gonzalez AD, Dlugovitzky DG, Bonfil RD, Scharovsky OG (2000) Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide. Eur J Cancer 36:1060
25. Mattei F, Schiavoni G, Belardelli F, Tough DF (2001) IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J Immunol 167:1179
26. Mohan K, Ding Z, Hanly J, Issekutz TB (2002) IFN-gamma-inducible T cell alpha chemoattractant is a potent stimulator of normal human blood T lymphocyte transendothelial migration: differential regulation by IFN-gamma and TNF-alpha. J Immunol 168:6420
27. Mokyr MB, Barker E, Weiskirch LM, Takesue BY, Pyle JM (1989) Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor. Cancer Res 49:4597
28. Mokyr MB, Dray S (1983) Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide. Cancer Res 43:3112
29. Mokyr MB, Hengst JC, Dray S (1982) Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors. Cancer Res 42:974
30. Mokyr MB, Rubin M, Newell KA, Prokhorova A, Bluestone JA (1993) Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan. J Immunol 151:4838
31. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M (1994) Functional role of type I and type II interferons in antiviral defense. Science 264:1918
32. Nagarkatti M, Toney DM, Nagarkatti PS (1989) Immunomodulation by various nitrosoureas and its effect on the survival of the murine host bearing a syngeneic tumor. Cancer Res 49:6587
33. Rani MR, Foster GR, Leung S, Leaman D, Stark GR, Ransohoff RM (1996) Characterization of beta-R1, a gene that is selectively induced by interferon beta (IFN-beta) compared with IFN-alpha. J Biol Chem 271:22878
34. Rani MR, Gauzzi C, Pellegrini S, Fish EN, Wei T, Ransohoff RM (1999) Induction of beta-R1/I-TAC by interferon-beta requires catalytically active TYK2. J Biol Chem 274:1891
35. Rosenblum MG, Yung WK, Kelleher PJ, Ruzicka F, Steck PA, Borden EC (1990) Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2′,5′-oligoadenylate synthetase and protein kinase activity. J Interferon Res 10:141
36. Sahasrabudhe DM, deKernion JB, Pontes JE, Ryan DM, O'Donnell RW, Marquis DM, Mudholkar GS, McCune CS (1986) Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J Biol Response Modif 5:581
37. Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, Belardelli F, Proietti E (2000) Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95:2024
38. Takesue BY, Pyle JM, Mokyr MB (1990) Importance of tumor-specific cytotoxic CD8+ T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy. Cancer Res 50:7641
39. Taniguchi T, Takaoka A (2002) The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol 14:111
40. Uze G, Lutfalla G, Mogensen KE (1995) Alpha and beta interferons and their receptor and their friends and relations. J Interferon Cytokine Res 15:3
41. Weiskirch LM, Bar-Dagan Y, Mokyr MB (1994) Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy. Cancer Immunol Immunother 38:215
42. Weiskirch LM, Baumgartel BA, Barker E, Mokyr MB (1991) Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers. Cancer Immunol Immunother 32:353
43. Yuan L, Kuramitsu Y, Li Y, Kobayashi M, Hosokawa M (1995) Restoration of interleukin-2 production in tumor-bearing rats through reducing tumor-derived transforming growth factor beta by treatment with bleomycin. Cancer Immunol Immunother 41:355